Dr. Kevin Fitzgerald, Ph.D. serves as Head of Research and Senior Vice President at Alnylam Pharmaceuticals, Inc. and served as its Vice President of Research. Dr. Fitzgerald joined Alnylam in 2005 as an Associate Director of Research and served in roles of increasing responsibility and leadership since that time. His achievements at Alnylam include leadership of RNAi delivery efforts, which resulted two clinically validated modes of siRNA delivery. He led multiple programs – including Alnylam’s PCSK9 program – from discovery through pre-clinical development, regulatory submissions and early clinical development. He was a Senior Research Scientist and Group Leader at Bristol Myers Squibb, where Dr. Fitzgerald contributed to the development of multiple pharmaceutical products and managed several technology and drug development alliances. He was a Lead Author and Co-author on Alnylam’s seminal papers in The Lancet and the New England Journal of Medicine, which demonstrated the effects of RNAi therapeutics in man. He has B.S. in Genetics from Cornell University and Ph.D. in Molecular Biology from Princeton University. He completed his Post-Doctoral Fellowship in Oncology at Harvard Medical School.

 Pharmaceutics & Drug Delivery Research